CNTB - Connect Biopharma Holdings Limited

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

1.1100

-0.0200

(-1.77%)

At close: 04:00PM EDT

Stock chart is not supported by your current browser

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Momentum

Performance Outlook

Short Term
2W - 6W
Mid Term
6W - 9M
Long Term
9M+

Previous Close	1.1300
Open	1.1800
Bid	1.0900 x 900
Ask	1.1000 x 2200
Day's Range	1.0900 - 1.1800
52 Week Range	0.6200 - 2.0800
Volume	92,771
Avg. Volume	645,714

Market Cap	61.096M
Beta (5Y Monthly)	-0.51
PE Ratio (TTM)	N/A
EPS (TTM)	-2.0800
Earnings Date	Apr 11, 2023
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	6.33

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CNTB

Learn more

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

All

GlobeNewswire
Connect Biopharma Announces Positive Long-Term Data from the Maintenance Period Through Week 48 of CN002 Phase 2 Icanbelimod Trial in Patients with Moderate-to-Severe Ulcerative Colitis
Icanbelimod demonstrated sustained clinical remission, a regulatory relevant efficacy endpoint, through Week 48 in 80% of patients who achieved clinical remission at Week 12 of the induction period.Icanbelimod continued to be well-tolerated, consistent with observed induction period safety data. SAN DIEGO, CA and TAICANG, China, June 01, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical com
GlobeNewswire
Connect Biopharma Reports Full Year 2022 Financial Results and Provides Business Update
CDE’s Pre-NDA Feedback Confirms CBP-201 for Atopic Dermatitis on Track for NDA Submission in China by End of First Quarter 2024 SAN DIEGO and TAICANG, SUZHOU, China, April 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced financial results for the year ended December 31, 2022 and recent corporate high
Benzinga
Connect Biopharma's Atopic Dermatitis Candidate Shows Rapid, Sustained Improvement Across All Body Regions
https://cdn.benzinga.com/files/images/story/2023/03/20/cntb.png?optimize=medium&dpr=2&auto=webp&crop=1200%2C800 Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD). The data exhibited that CBP-201 led to rapid and sustained improvement in AD signs and symptoms across all four body regions, compared to the placebo. EASI subscores improved in all four body regions across 16 weeks of t
Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis China Pivotal Study Showed Rapid Relief of Patient Symptoms
SAN DIEGO & TAICANG, China & SUZHOU, China, March 18, 2023--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD) showed rapid relief from symptoms, as early as week one in some cases, and no efficacy plateau at Week 16. The study
MarketWatch
Connect Biopharma stock up more than 40% after trial data
MARKET PULSE Connect Biopharma Holdings Ltd. (CNTB) stock rose more than 40% in the extended session Friday after the company said that analysis of a trial involving one of its therapies to treat moderate-to-severe atopic dermatitis showed “rapid and sustained improvement” in signs and symptoms of the illness as compared to a placebo.
Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis Global Phase 2b Data Showed Rapid and Sustained Improvement Across all Body Regions
SAN DIEGO & TAICANG, China & SUZHOU, China, March 17, 2023--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, announced that post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD) showed that CBP-201 led to rapid and sustained improvement in AD signs and symptoms across all four body regions, w
Business Wire
Connect Biopharma CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted for Presentation at the American Academy of Dermatology (AAD) Annual Meeting
SAN DIEGO & TAICANG & SUZHOU, China, March 06, 2023--Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that two abstracts from its CBP-201 clinical development program in atopic dermatitis (AD) have been accepted for presentation at the American Academy of Dermatology (AAD), March 17-21, 2023, in New Orleans, LA. Specifically, da
GlobeNewswire
Connect Biopharma to Present at SVB Securities Global Biopharma Conference and Participate in BioCom California
SAN DIEGO and TAICANG, SUZHOU, China, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting, and hosting one-on-one meetings, at the following conferences in February and March 2023: SVB Securities Global Biopharma Conference, February 15 at 4:10 pm Eastern/1:10pm Pacific. To view the presentation live please, fo
Simply Wall St.
Is Connect Biopharma Holdings (NASDAQ:CNTB) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
GlobeNewswire
Connect Biopharma Provides Business and Clinical Development Program Update
Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of potential partnership opportunities to advance the global AD Phase 3 program Progress of China pivotal AD trial remains on track with completion of 36-week Stage 2 expected in H2 2023 SAN DIEGO and TAICANG, SUZHOU, China, Dec. 30, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq:
GlobeNewswire
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that Zheng Wei, PhD, Co-Founder and CEO of Connect Biopharma will present a corporate update on January 9, at 9:00 am PST, during the upcoming Biotech Showcase taking place in person January 9 – 11, 2023. Conn
GlobeNewswire
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced that, on November 28, 2022, it received a letter from the Listings Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) indicating that, for the last 30 consecutive business days, the bid price fo
GlobeNewswire
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it will be presenting and/or hosting one-on-one meetings at the following upcoming investor and scientific conferences: 6th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases, Boston, November 1-3; Connect CEO Zheng Wei w
Benzinga
Connect Biopharma Lead Candidate Aces Pivotal Atopic Dermatitis Trial In Chinese Patients
Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced topline results for the primary analysis population of the pivotal trial of CBP-201, in patients with moderate-to-severe atopic dermatitis (AD) in China. This trial evaluates the efficacy and safety of CBP-201 as well as the potential for an extended CBP-201 dosing interval during the maintenance phase of treatment. The primary endpoint of IGA of 0 or 1 ("clear" or "almost clear") with at least 2 grades of reduction at Week 16 from base
GlobeNewswire
CORRECTING and REPLACING -- Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in the "About the Trial" section, the fourth sentence should read "Stage 2 36-week maintenance period", not "Stage 2 16-week maintenance period" as previously stated. The corrected release follows: All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with
GlobeNewswire
Connect Biopharma Reports CBP-201 Achieved All Primary and Key Secondary Endpoints in Pivotal Atopic Dermatitis (AD) Trial in China
All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe ADSafety and tolerability results for CBP-201 consistent with targeting the IL-4Rα pathwayData support advancing the regulatory discussions with the CDE for submitting an NDA in ChinaConference call to discuss these data will be held today at 5:30am PDT/8:30am EDT SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq
GlobeNewswire
Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis
Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD).
Thomson Reuters StreetEvents
Edited Transcript of CNTB.OQ earnings conference call or presentation 13-Sep-22 8:30pm GMT
Q2 2022 Connect Biopharma Holdings Ltd Earnings Call
GlobeNewswire
Connect Biopharma Reports First Half 2022 Financial Results and Provides Business Update
– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 – – Company to Host Conference Call Today at 4:30 p.m. ET – SAN DIEGO and TAICANG, China, Sept. 13, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global, clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced financial results f
GlobeNewswire
Connect Biopharma to Report First Half 2022 Financial Results on September 13
Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report financial results for the six-month period ended June 30, 2022, on Tuesday, September 13, after market close. Following the press release, the Company will host a web
Benzinga
Connect Biopharma's Candidate For Skin Disease-Associated Itch Shows Encouraging Safety Profile
Connect Biopharma Holdings Limited (NASDAQ: CNTB) has completed its first-in-human Phase 1 study of CBP-174 in healthy adults. CBP-174, a highly selective, peripherally acting H3 receptor antagonist drug candidate, is in development to treat pruritus (itch) associated with allergic and inflammatory skin diseases, including atopic dermatitis. CBP-174, administered orally, was observed to be safe and well-tolerated across eight dose escalation cohorts evaluated up to a maximum dose of 16 mg or pla
GlobeNewswire
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose Study
– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated – SAN DIEGO and TAICANG, SUZHOU, China, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global, clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, today announced it successfully completed its first-in-
Benzinga
Connect Biopharma Sees CBP-201 Topline Data From China Atopic Dermatitis Trial This Year
The Center for Drug Evaluation of the National Medical Products Administration in China has signed off Connect Biopharma Holdings Limited's (NASDAQ: CNTB) primary analysis of its ongoing pivotal trial for its lead product candidate CBP-201 in atopic dermatitis. The company will analyze data from the Stage 1 16-week treatment period based on CBP-201 on 255 patients. As a result, Connect Biopharma plans to report this trial's top-line results by year-end, earlier than initially planned. Also Read:
GlobeNewswire
Connect Moves Forward CBP-201 Top-Line Results Timeline for Pivotal China Atopic Dermatitis Trial to Second Half 2022
— Connect to Evaluate Efficacy and Safety Data on 255 Patients Already Enrolled — — Expected Timing for Potential NDA Approval in China Remains Unchanged and is Targeted for 2025 — SAN DIEGO and TAICANG, SUZHOU, China, July 11, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”) today announced it has been informed by the Center for Drug Evaluation of the National Medical Products Administration (CDE), that it can conduct primary anal